Company Profile

Industry Sector: Biopharmaceutical

Company Overview: Oligomerix has developed a novel and highly differentiated approach to developing disease-modifying therapeutics for Alzheimer’s disease (AD) and related neurodegenerative disorders. The Company has pioneered targeting tau oligomers and their roles in disease progression and impairment of memory formation to develop small molecule and antibody based therapeutic approaches and biomarkers for drug development and diagnostic uses. The Company has assembled a core team that will advance its early leads through preclinical testing to identify clinical candidates for advancement with strategic partners.

Target Market(s): Alzheimer’s Disease and other tauopathies

Market Need: AD costs US society over $215 billion per year making it the most costly disease. The prevalence is increasing worldwide, and there are no FDA approved disease-modifying drugs.

Plan & Strategy: A licensing agreement and research collaboration agreement is being sought with a pharmaceutical partner with global reach enabling the acceleration of therapeutic and diagnostic intervention through clinical evaluation, regulatory submission and approval.

Management

Leadership:
- Victor Micati, MBA, Chairman
- James Moe, Ph.D., MBA Founder, Director, President & CEO
- Elliot Davidowitz, Ph.D., Founder, Chief Scientist
- Jack Pasini, Director, Chief Commercial Officer
- David Dantzker, MD, Wheatley Partners, Director
- Doug Durand, Durand Associates, Director

Consultants: James Hendrix, Ph.D., Director of Chemistry; Albert Yehaskel, MBA, Director Regulatory Affairs; Philip Hahn, JD, Deal Negotiations

Key Value Drivers

Technology*: Oligomerix is advancing small molecule inhibitors of tau oligomer formation and developing antibody fragments that specifically target tau oligomer structures. The Company is also targeting the proteolytic activity of tau oligomers using small molecule and antibody approaches. The antibodies have potential immunotherapeutic, biomarker and diagnostic uses.

Competitive Advantage: The combination of recent progress in neuroscience and the consistent disappointment from clinical trials targeting the amyloid cascade have highlighted tau oligomers as a key alternative target in the search for disease-modifying AD therapeutic interventions. Oligomerix has the differentiated strategy of targeting tau oligomers, whereas competitors target tau fibrils that are no longer thought to be the acutely neurotoxic aggregates of tau protein. Oligomerix has discovered a novel toxic mechanism for tau in which tau becomes a protease upon the formation of an oligomer structure leading to both self-cleavage and fragmentation of other proteins important for neuron function. The Company is uniquely developing small molecule inhibitors of this activity and monoclonal antibodies against the epitopes created by this activity. An excellent scientific and commercialization team has been assembled, and an IP strategy is being pursued to maintain its competitive advantage.

*Technology funded by the National Institute on Aging (NIA AG029777 and AG033474) and being commercialized under the NIH-CAP, a grant from the Alzheimer's Drug Discovery Foundation, equity investment, and tax credits from New York State and New York City.

Product Pipeline

- Small molecule inhibitors of tau oligomer formation (lead optimization phase to select IND candidates and PET ligands)
- Small molecule inhibitors of tau oligomer protease activity (discovery phase)
- Antibodies specific for tau oligomer structural epitopes and for cut ends of proteins generated by tau protease activity
- Tauopathy Platform - applicable to over 20 different neurodegenerative diseases including AD and chronic traumatic encephalopathy (CTE)
  - HTS assay
  - Cell assays
  - Tau protease assay
  - In vivo models (tau acute model for cognitive impairment)